2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1452

Pauciimmune and Immune Mediated Pulmonary Capillaritis in Children
Abstract Number: 1453

Surveillance of Periodic Fever Syndromes in Canada
Abstract Number: 1454

Familial Mediterranean Fever in Childhood: a Single Center Experience
Abstract Number: 1455

Juvenile Spondyloarthropathies: a Single Center Experience
Abstract Number: 1456

Macrophage Activation Syndrome and Familial Hemophagocytic Lymphohistiocytosis: Is Their Clinical Phenotype Really Similar?
Abstract Number: 1457

An Organ Based Diagnostic Approach to Macrophage Activating Syndrome in Children Demonstrates Impaired Reticuloendothelial System Clearance
Abstract Number: 1458

Association of Chronic, Extreme Elevation of Serum IL-18 with the Development of Macrophage Activation Syndrome in a Cohort of Autoinflammatory Disease Patients: A Potential Diagnostic Biomarker?
Abstract Number: 1459

Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 1460

Association of Vitamin D Receptor Polymorphism with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 1461

Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1462

Farber Disease: Important Differential Diagnostic Information for JIA and Other Inflammatory Arthritis Phenotypes Is Revealed By Data from the Largest Clinical Cohort to Date
Abstract Number: 1463

Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1464

Assessment of Left Ventricle Functions in Children with Familial Mediterranean Fever with Tissue Doppler and Strain Echocardiography
Abstract Number: 1465

Musculoskeletal Anomalies in Children with Trisomy 21
Abstract Number: 1466

Assessment of Transition Readiness in Adolescents and Young Adults with Chronic Health Conditions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].